Search clinical trials for: DMX-1002

Total 5132 results

Staidson (Beijing) Biopharmaceuticals Co., Ltd

Terminated

A Study of STSA-1002 Combined With STSA-1005 in Healthy Subjects

Healthy Subject

China
Salvat

Completed

A Clinical Trial to Assess the Effect of HC-SVT-1001 and HC-SVT-1002 in the Surgical Treatment of Atrophic Pseudarthrosis of Long Bones (Bonecure) (Bonecure)

Pseudoarthrosis

Spain
University of California, Los Angeles
Tiny Blue Dot Foundation; The Dana Foundation

Terminated

Thalamic Low Intensity Focused Ultrasound in Brain Injury (LIFUP)

Brain Injuries | Consciousness Disorders

United States
EuBiologics Co.,Ltd

Completed

Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines

Glabellar Frown Lines

Korea, Republic of
Centocor Ortho Biotech Services, L.L.C.

Completed

A Study of Human Rhinovirus Type 16 (HRV-16) Following Administration in the Nose of Healthy Adult Volunteers

Healthy

United States
Conjupro Biotherapeutics, Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors

Solid Tumor

United States
University Health Network, Toronto
The Physicians' Services Incorporated Foundation

Completed

The Influence of Vibration on Bone Mineral Density in Women Who Have Weak Bones After Menopause

Osteoporosis | Osteopenia | Bone Density | Post-Menopause

Canada
PhotonMD, Inc

Completed

Modulated Light Therapy in Participants With Pattern Hair Loss

Androgenetic Alopecia

Australia
OliPass Australia Pty Ltd
Novotech (Australia) Pty Limited

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Multiple Subcutaneous Doses of OLP-1002

Osteoarthritis

Australia
gicare Pharma Inc.
Algorithme Pharma Inc

Completed

Study on Analgesia of GIC-1001 & GIC-1002 on Visceral Pain, Rectal Sensory Threshold Using the Barostat Method

Pain | Cancer | Colonic Disease

Canada
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Recruiting

To Evaluate The Safety and Initial Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome

Acute Respiratory Distress Syndrome

China
Yonsei University

Completed

Effect of Perioperative Iron Isomaltoside 1000 Administration on Transfusion Requirements in Patients Undergoing Complex Valvular Heart Surgery: a Randomized Clinical Trial

Complex Valvular Heart Surgery

Korea, Republic of
Capricor Inc.

Completed

Halt cardiomyOPathy progrEssion in Duchenne (HOPE-OLE) (HOPE-OLE)

Duchenne Muscular Dystrophy

United States
Capricor Inc.

Completed

HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne) (HOPE)

Duchenne Muscular Dystrophy | Cardiomyopathy

United States
Nestlé

Completed

Glycemic Response in Persons With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Chong Kun Dang Pharmaceutical

Unknown

Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393

T2DM (Type 2 Diabetes Mellitus)

Korea, Republic of
GlaxoSmithKline

Completed

A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia

Leukaemia, Lymphocytic, Chronic

Korea, Republic of, Japan
Merck Sharp & Dohme LLC

Completed

Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | Genital Warts | Human Papilloma Virus
DemeRx IB, Inc.
Hammersmith Medicines Research; ERT: Clinical Trial Technology Solutions; MAC...

Recruiting

A Study of Oral Ibogaine in Opioid Withdrawal

Opiate Withdrawal Syndrome

United Kingdom
Medical University of Warsaw

Unknown

Effect of Passive Leg Raising for Fluid Responsiveness

Cardiac Output, Low | Body Fluid Retention | Impedance

Poland
Neurological Associates of West Los Angeles

Enrolling by invitation

Focused Ultrasound for the Treatment of ADHD Symptoms

ADHD

United States
Quark Pharmaceuticals

Completed

A Study to Evaluate Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery

Acute Kidney Injury

United States, Canada, Germany
Massachusetts General Hospital

Active, not recruiting

Neuromodulation of Mind-Wandering in Depression

Depression

United States
Quark Pharmaceuticals

Completed

QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant (ReGIFT)

Delayed Graft Function

United States, Spain, Canada, Australia, Netherlands, Germany, Belgium, France, Argentina, Brazil, Czechia
Wake Forest University Health Sciences

Active, not recruiting

SNIFF Multi-Device Study 2

Cognitive Impairment | Mild Cognitive Impairment

United States
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Completed

The Safety and Tolerability of STSA-1002 Following Intravenous Infusion in Healthy Subjects

Healthy

United States
Quark Pharmaceuticals

Terminated

QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery

Cardiac Surgery

United States, Germany, Spain, Australia, Austria, Canada, New Zealand, United Kingdom, Belgium, Czechia, France
Quark Pharmaceuticals

Completed

I5NP for Prophylaxis of Delayed Graft Function in Kidney Transplantation

Delayed Graft Function | Other Complication of Kidney Transplant

United States, Spain, Germany, France, Canada
Quark Pharmaceuticals

Terminated

A Dose Escalation and Safety Study of I5NP to Prevent Acute Kidney Injury (AKI) in Patients at High Risk of AKI Undergoing Major Cardiovascular Surgery (QRK.004)

Acute Kidney Injury | Acute Renal Failure

United States
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Completed

The Safety of STSA-1002 Following Intravenous Infusion in Healthy Subjects

Healthy

China
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Completed

The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects

Antineutrophil Cytoplasmic Antibody Associated Vasculitis

United States
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Completed

A Study of STSA-1002 in Healthy Subjects

Healthy Subject

China
Massachusetts General Hospital

Withdrawn

Focused Ultrasound Neuromodulation for Treatment of Temporal Lobe Epilepsy (LIFUP)

Low Intensity Ultrasound Pulsarions
Biogen

Completed

Tecfidera and the Gut Microbiota (TECONGUT)

Multiple Sclerosis, Relapsing-Remitting

Norway
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant (CARAMEL 2)

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Attaya Suvannasankha
National Cancer Institute (NCI)

Terminated

Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy

Refractory Multiple Myeloma

United States
Rennes University Hospital

Recruiting

Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years (STOP-I-SEP) (STOP-I-SEP)

Multiple Sclerosis

France
Hoffmann-La Roche

Completed

Accu-Chek® CONNECT at School (CATS) Pediatric Study (CATS)

Diabetes Mellitus, Type 1

United States
Asklepios Biopharmaceutical, Inc.

Recruiting

Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure (GenePHIT)

Congestive Heart Failure

United States
Capricor Inc.

Active, not recruiting

Open-label Extension of the HOPE-2 Trial (HOPE-2-OLE)

Duchenne Muscular Dystrophy

United States
Capricor Inc.

No longer available

CAP-1002 in Severe COVID-19 Disease

COVID-19

United States
Massachusetts General Hospital
National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health... and other collaborators

Recruiting

Impact of Intravenous Iron Repletion On Mechanisms of Exercise InTolerance in HFpEF (IRONMET-HFpEF) (IRONMETHFpEF)

Iron-deficiency | Heart Failure With Preserved Ejection Fraction

United States
KGK Science Inc.
ChromaDex, Inc.

Completed

A Study Investigating the Effects of Niagen™ in Healthy Adults. (15NRHC)

Bioavailability

Canada
Fractyl Health Inc.

Completed

Effect of Duodenal Mucosal Resurfacing (DMR) Using the Revita System in the Treatment of Type 2 Diabetes (T2D)

Diabetes Mellitus, Type 2 | Noninsulin-Dependent Diabetes Mellitus

United Kingdom, Belgium, Brazil, Italy, Netherlands
Digestome Therapeutics

Completed

A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of DGX-001

Depressive Disorder

Australia
Medicines for Malaria Venture
Washington University School of Medicine; Sanaria Inc.; Institute of Tropical... and other collaborators

Completed

Safety, Tolerability and Chemoprotective Activity of P218 in PfSPZ Challenge Model

Malaria

Belgium
Medical University of Warsaw

Completed

Changes in Volumetric Hemodynamic Parameters Induced by Fluid Removal on Hemodialysis (CI/HD)

End Stage Renal Failure on Dialysis | Cardiac Output, Low | Body Fluid Retention | Impedance

Poland
Capricor Inc.
National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health... and other collaborators

Unknown

Dilated cardiomYopathy iNtervention With Allogeneic MyocardIally-regenerative Cells (DYNAMIC) (DYNAMIC)

Heart Failure | Ischemic Cardiomyopathy | Nonischemic Cardiomyopathy | Dilated Cardiomyopathy (DCM)

United States
MedImmune LLC

Completed

Phase 1 Single-ascending Dose Study to Evaluate Safety and Tolerability of MEDI4920 in Healthy Adults

Healthy Volunteer

United Kingdom
Wake Forest University Health Sciences
Hieu Nguyen, MS - Biostatician; McKenzie Isreal, MPH - project manager; Casey...

Completed

Dragon Ambient eXperience (DAX) Copilot Evaluation (DAX)

Automated Clinical Documentation

United States

Search clinical trials for: DMX-1002

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Italy

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations